

Org nr 556966-4955  
February 11, 2026



## **Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study**

**Gothenburg, February 11, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today announces that an abstract presenting data from the ongoing Phase I/Ia CARMA study has been accepted for presentation at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, Ireland, taking place May 6–9, 2026. The poster presentation will highlight complete metabolic response in four of six patients treated with the iTANK-armed CAR T-cell therapy ELC-301 in the first two cohorts of the study.**

Margareth Jorvid, regulatory expert and board member of Elicera Therapeutics, will participate in a networking session to present the company's scientific poster titled " iTANK PLATFORM DERIVED ELC-301 FOR LYMPHOMA: COMPLETE REMISSION DATA REPORTED FOR FOUR OF SIX PATIENTS IN FIRST TWO COHORTS OF CARMA-01 STUDY".

ISCT brings together leading researchers, clinicians, and industry experts in cell and gene therapy from around the world. The primary goal of the conference is to facilitate the exchange of new scientific advancements, technological innovations, and clinical insights in the rapidly evolving field of cell and gene therapy.

For more information: <https://www.isctglobal.org/annual-meeting/home>

### **For further information, please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)  
Phone: +46 (0) 703 31 90 51  
[jamal.elmosleh@elicera.com](mailto:jamal.elmosleh@elicera.com)

### **Certified Advisor**

DNB Carnegie Investment Bank AB (publ)

### **About the CARMA Study**

CARMA is a phase I/Ia clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase Ia). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase Ia will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third

dcohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge.

### **About ELC-301**

ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company's iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen—a molecule visible on the surface of cancer cells—and enables the T-cells to locate, bind to, and destroy the cancer cells.

### **About the iTANK platform**

The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in *Nature Biomedical Engineering* in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers" (DOI number: 10.1038/s41551-022-00875-5) can be found here: <https://www.nature.com/articles/s41551-022-00875-5>. More information about iTANK platform is available here: <https://www.elicera.com/technology>

### **About Elicera Therapeutics AB**

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit [www.elicera.com](http://www.elicera.com).